Influence of regulatory T cells on resistance mechanisms to epidermal growth factor receptor inhibitors: an observational study
Not Applicable
- Conditions
- ung cancer and colon cancer treated with epidermal growth factor receptor inhibitors
- Registration Number
- JPRN-UMIN000009012
- Lead Sponsor
- Oita University Faculty Of Medicine Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients had a medical history of treatment with gefitinib, erlotinib,afatinib, cetuximab, or panitumumab. 2.The patient has received systemic chemotherapy within 21 days or therapeutic radiation therapy within 14 days prior to the first dose of study therapy. Palliative radiation is permitted. 3.Patients have severe complications, as active infection and poorly controlled diabetes. 4.Patients has allergy, which is expected to interrupt the study. 5.Pregnant women 6.Multiple primary cancer. 7.Patients regularly use corticosteroids and immunosuppressive drugs. Inhalation and topical use are permitted.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relevance between Treg distribution in skin/circulation and progression free survival
- Secondary Outcome Measures
Name Time Method